Creative Planning’s ENDRA Life Sciences NDRA Stock Holding History

Creative Planning’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1	Closed	-$48K	–	2075
2019 Q3	$48K	Hold	1	–	–	﹤0.01%	1791
2019 Q2	$68K	Hold	1	–	–	﹤0.01%	1785
2019 Q1	$66K	Hold	1	–	–	﹤0.01%	1755
2018 Q4	$53K	Buy	+1	New	+$116K	﹤0.01%	1707

Other funds holding NDRA

IAM

ICM Asset Management Spokane, Washington $18.1M AUM 30.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

WEC

Winslow Evans & Crocker Boston, Massachusetts $528M AUM 30.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VWM

Vigilare Wealth Management Scottsdale, Arizona $326M AUM 21.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Creative Planning's NDRA Position: Q4 2019 in Review

Creative Planning sold out of ENDRA Life Sciences (NDRA) in Q4 2019, closing a stake of 1 share — an estimated $48K sold.

Creative Planning first reported a position in NDRA in Q4 2018 and held it in 4 quarters. The position peaked at $68K in Q2 2019. 5 funds tracked by Wall St. Rank hold NDRA as of Q4 2019.

Creative Planning reported no remaining ENDRA Life Sciences position as of Q4 2019 after selling out during the quarter.
Creative Planning sold 1 ENDRA Life Sciences share in Q4 2019, an estimated $48K.
Creative Planning first reported a position in ENDRA Life Sciences in Q4 2018 and held it in 4 quarters.
Creative Planning's ENDRA Life Sciences position peaked at $68K in Q2 2019.
5 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q4 2019.

Based on Creative Planning's 13F filing for Q4 2019, filed 30 Jan 2020.